NCT07759778Not yet recruitingPhase 4
Oliceridine-Propofol Dose for Gastroscope Insertion in Obese Patients
Exploration of the Effective Dose of Oliceridine Combined With Propofol for Gastroscope Insertion in Obese Patients Undergoing Painless Gastrointestinal Endoscopy
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to find the right dose of two medications, oliceridine and propofol, when used together for sedation in patients with obesity undergoing a painless gastroscope procedure. Currently, standard sedation methods using other opioids can sometimes cause breathing problems, especially in patients with obesity. Oliceridine is a newer medication that may provide good pain relief with a lower risk of these side effects. However, the best dose of propofol when combined with oliceridine for this specific patient group is not yet clear. This study will enroll patients with obesity (BMI ≥ 28 kg/m²) who are scheduled for a routine painless gastroscopy. Participants will receive the study medications during their procedure, and the medical team will carefully monitor their vital signs and sedation level. The study aims to find the most effective and safe dose combination to help guide future clinical practice.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Lu Yi
- Diseases
- Obesity
- NCT number
- NCT07759778
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 80
- From 1 Aug 2026 to the primary completion date, 28 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Long-term use of opioids (regular use of opioids for more than 7 days within 3 months before operation)
Other illness
- Known to be allergic to drugs used in the examination process
- Diagnosed respiratory diseases (asthma, bronchitis, chronic obstructive pulmonary disease, pulmonary embolism, pulmonary edema, lung cancer or upper respiratory tract infection)
- Cardiovascular diseases (heart failure, unstable angina pectoris, myocardial infarction or arrhythmia) have been diagnosed
- Current hepatic insufficiency (Child-Pugh grade B or above) or renal insufficiency (estimated glomerular filtration rate \< 60 ml/min/1.73 m2)
- History of difficult airway (Mallampati Grade IV or expected difficult airway)
- Mental illness or cognitive dysfunction can not cooperate
Other
- Pregnant or lactating women
Who the study is looking for
- 18-65 years old, regardless of sex
- BMI≥28 kg/m2
- The American Society of Anesthesiologists (ASA) has a rating of II-III
- Plan to undergo elective painless digestive endoscopy
- The subjects understand the purpose and steps of this experiment, voluntarily participate in this experiment, and sign a written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.